Archive for Mary Crowley Cancer Research - Medical City Dallas

A Phase I/II, First-in-Human, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients with Advanced Solid Tumors

A Phase 1, First in Human, Dose-Escalation Study of TORL-3-600 in Participants with Advanced Cancer

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors

Phase 1/1b, Multicenter, Open-LabeL, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

A Multi-Regional, Open-Label, Dose Escalation and Dose Expansion Phase I Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants with HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

“A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also knownas MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA)Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer”

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients with High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors

« Older Entries
Newer Entries »